-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $240

Benzinga·07/30/2026 17:22:25
Listen to the news
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $242 to $240.